{"id":965,"date":"2015-05-06T08:41:48","date_gmt":"2015-05-06T08:41:48","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=965"},"modified":"2016-03-17T19:15:47","modified_gmt":"2016-03-17T19:15:47","slug":"poxel-enyo-pharma-signent-accord-de-licence","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/poxel-enyo-pharma-signent-accord-de-licence\/","title":{"rendered":"POXEL et ENYO Pharma signent un accord de licence sur le programme agoniste FXR de POXEL"},"content":{"rendered":"<p>Lyon, France, 6 mai 2015, &#8211; POXEL (Euronext &#8211; FR0012432516 &#8211; \u00e9ligible PEA-PME) soci\u00e9t\u00e9 biopharmaceutique fran\u00e7aise ind\u00e9pendante sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de m\u00e9dicaments contre le diab\u00e8te de type 2 et ENYO Pharma SAS, une soci\u00e9t\u00e9 nouvellement cr\u00e9\u00e9e, centr\u00e9e sur le traitement des infections virales aigu\u00ebs et chroniques, ont annonc\u00e9 aujourd&#8217;hui la signature d&#8217;un contrat de licence en vertu duquel ENYO aura acc\u00e8s aux compos\u00e9s agonistes du r\u00e9cepteur FXR (r\u00e9cepteur farneso\u00efde X) de POXEL pour des indications th\u00e9rapeutiques en infectiologie avec une conservation de droits pour POXEL sur des indications incluant les maladies cardiovasculaires et du m\u00e9tabolisme.<\/p>\n<a href=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2016\/02\/20150506_poxel_out-license_pr_final_fr.pdf\" target=\"_blank\" rel=\"\" target=\"_blank\" class=\"tano-file\"><span class=\"tano_download_icon\"><\/span><span class=\"tano_file_title\">T\u00e9l\u00e9charger le communiqu\u00e9 complet (PDF)<\/span><\/a>\n","protected":false},"excerpt":{"rendered":"<p>Lyon, France, 6 mai 2015, &#8211; POXEL (Euronext &#8211; FR0012432516 &#8211; \u00e9ligible PEA-PME) soci\u00e9t\u00e9 biopharmaceutique fran\u00e7aise ind\u00e9pendante sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de m\u00e9dicaments contre le diab\u00e8te de type 2 et ENYO Pharma SAS, une soci\u00e9t\u00e9 nouvellement cr\u00e9\u00e9e, centr\u00e9e sur le traitement des infections virales aigu\u00ebs et chroniques, ont annonc\u00e9 aujourd&#8217;hui la signature d&#8217;un contrat de licence en vertu duquel ENYO aura acc\u00e8s aux compos\u00e9s agonistes du r\u00e9cepteur FXR (r\u00e9cepteur farneso\u00efde X) de POXEL pour des indications th\u00e9rapeutiques en infectiologie avec une conservation de droits pour POXEL sur des indications incluant les maladies cardiovasculaires et du m\u00e9tabolisme.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/poxel-enyo-pharma-signent-accord-de-licence\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-965","post","type-post","status-publish","format-standard","hentry","category-press-releases-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"adminENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/adminenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/press-releases-fr\/\" rel=\"category tag\">Press releases<\/a>","rttpg_excerpt":"Lyon, France, 6 mai 2015, &#8211; POXEL (Euronext &#8211; FR0012432516 &#8211; \u00e9ligible PEA-PME) soci\u00e9t\u00e9 biopharmaceutique fran\u00e7aise ind\u00e9pendante sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de m\u00e9dicaments contre le diab\u00e8te de type 2 et ENYO Pharma SAS, une soci\u00e9t\u00e9 nouvellement cr\u00e9\u00e9e, centr\u00e9e sur le traitement des infections virales aigu\u00ebs et chroniques, ont annonc\u00e9 aujourd&#8217;hui la signature d&#8217;un contrat de&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=965"}],"version-history":[{"count":3,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/965\/revisions"}],"predecessor-version":[{"id":968,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/965\/revisions\/968"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}